FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.

@article{Wu2016FK228AT,
  title={FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.},
  author={Yihan Wu and Li Dong and Sarula Bao and Meiling Wang and YongLi Yun and Runxiu Zhu},
  journal={Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie},
  year={2016},
  volume={84},
  pages={462-469}
}
Temozolomide is a novel cytotoxic agent currently used as first-line chemotherapy for glioblastoma multiforme (GBM). Romidepsin (FK228), a histone deacetylase inhibitor, is a promising new class of antineoplastic agent with the capacity to induce growth arrest and/or apoptosis of cancer cells. However, combination of the two drugs in glioma remains largely… CONTINUE READING